This transcript has been edited for clarity.
Martha Grogan, MD: Hello, and welcome back to the Mayo Clinic–Medscape Cardiology video series. I'm Martha Grogan. I am the director of the Cardiac Amyloid Clinic at Mayo Clinic in Rochester, Minnesota.
Today I'm really thrilled to have my colleagues with me, Dr Julie Rosenthal, who is the director of the Cardiac Amyloid Program at Mayo Clinic in Arizona, and Dr Melissa Lyle, who is the cardiac amyloid lead for the Multidisciplinary Amyloid Clinic at Mayo Clinic in Florida. Welcome, Julie and Melissa.
We are going to focus on the new transthyretin amyloidosis (ATTR) therapies today, but I am just going to briefly mention that cardiologists should know that amyloid light-chain amyloidosis (AL) treatment is really improving, especially with the use of daratumumab. This is really a game changer, and with all types of amyloidosis we are now seeing improved outcomes.
We are going to briefly talk a little bit about what is transthyretin amyloid and what are the drugs that we have to treat this condition. Transthyretin is a protein that we all make; it is produced in the liver, and it transports thyroid hormone and retinol binding protein throughout the body.
Amyloidosis
Diagnosing Cardiac Amyloidosis: 5 Things to Know
Primary Systemic Amyloidosis
Nodular Localized Cutaneous Amyloidosis
COMMENTARY
Transthyretin Amyloid and New Treatment Options
Martha Grogan, MD; Melissa A. Lyle, MD; Julie L. Rosenthal, MD
DisclosuresDecember 06, 2021
Editorial Collaboration
Medscape &
This transcript has been edited for clarity.
Martha Grogan, MD: Hello, and welcome back to the Mayo Clinic–Medscape Cardiology video series. I'm Martha Grogan. I am the director of the Cardiac Amyloid Clinic at Mayo Clinic in Rochester, Minnesota.
Today I'm really thrilled to have my colleagues with me, Dr Julie Rosenthal, who is the director of the Cardiac Amyloid Program at Mayo Clinic in Arizona, and Dr Melissa Lyle, who is the cardiac amyloid lead for the Multidisciplinary Amyloid Clinic at Mayo Clinic in Florida. Welcome, Julie and Melissa.
We are going to focus on the new transthyretin amyloidosis (ATTR) therapies today, but I am just going to briefly mention that cardiologists should know that amyloid light-chain amyloidosis (AL) treatment is really improving, especially with the use of daratumumab. This is really a game changer, and with all types of amyloidosis we are now seeing improved outcomes.
We are going to briefly talk a little bit about what is transthyretin amyloid and what are the drugs that we have to treat this condition. Transthyretin is a protein that we all make; it is produced in the liver, and it transports thyroid hormone and retinol binding protein throughout the body.
Credits
Image 1: Mayo Clinic
Image 2: Mayo Clinic
© 2021 Mayo Clinic
Cite this: Transthyretin Amyloid and New Treatment Options - Medscape - Dec 06, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Martha Grogan, MD
Associate Professor of Medicine, Mayo Clinic School of Medicine, Rochester, Minnesota
Disclosure: Martha Grogan, MD, has disclosed the following relevant financial relationships:
Received research grants from: Pfizer; Alnylam; Eidos; Prothena
Melissa Lyle, MD
Assistant Professor of Medicine, Mayo Clinic School of Medicine, Rochester, Minnesota; Senior Associate Consult, Mayo Clinic, Jacksonville, Florida
Disclosure: Melissa Lyle, MD, has disclosed no relevant financial relationships.
Julie L. Rosenthal, MD
Assistant Professor of Medicine, Mayo Clinic School of Medicine, Rochester, Minnesota
Disclosure: Julie L. Rosenthal, MD, has disclosed the following relevant financial relationships:
Served as director, partner, employee, advisor or trustee for: Pfizer; Alnylam; Ad Board
Served as site PI for: Akcea Cardio Transform